Summary: Nature Biotechnology spoke to Harvey Berger about developing Iclusig, the difference between managing a patient's health and running a company, and how a public entity deals with bad news.
Summary: Nature Biotechnology spoke to Harvey Berger about developing Iclusig, the difference between managing a patient's health and running a company, and how a public entity deals with bad news.